Tag: X

Visitors of All Ages are Welcome to a Special Edition of Movies & Bites, Learn the Art of Floral Arrangement, and Experience the Design, Utility and Artistry of Samurai Weaponry

-  500 subjects enrolled across the United States, the United Kingdom, France, Czech Republic, Switzerland, China, Taiwan, and Australia

SHREWSBURY, United Kingdom, July 02, 2025 (GLOBE NEWSWIRE) -- Lightchain AI, an AI-native decentralized infrastructure platform, today announced the start of its Final Bonus Phase, following the successful completion of all 15 presale stages and the achievement of a major milestone—$21.1 million raised from a global community of early contributors. This final round offers a fixed price of $0.007125 per LCAI token, providing one last opportunity for participants ahead of the mainnet launch scheduled for July 2025.

旧金山, July 02, 2025 (GLOBE NEWSWIRE) -- 新兴在线市集平台、OfferUp 竞争对手 Ditchit 以极具硅谷颠覆精神的行动引爆舆论——收购并爆破原重达 560 磅、曾矗立于 Twitter 旧金山总部顶楼的 Twitter 飞鸟标志。

三藩市, July 02, 2025 (GLOBE NEWSWIRE) -- 在一場充分展現出矽谷顛覆性精神的戲劇性行動中，新興網上交易平台及 OfferUp 的競爭對手 Ditchit，透過收購及引爆原本矗立於 Twitter 三藩市總公司大樓頂部、重達 560 磅的 Twitter 小鳥標誌而登上新聞頭條。

NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Laser Photonics Corporation (“Laser Photonics” or the “Company”) (NASDAQ:LASE) on behalf of Laser Photonics stockholders. Our investigation concerns whether Laser Photonics has violated the federal securities laws and/or engaged in other unlawful business practices.

SHREWSBURY, United Kingdom, July 01, 2025 (GLOBE NEWSWIRE) -- Lightchain AI, the AI-native blockchain infrastructure platform, has entered its Bonus Round after successfully completing 15 presale stages and raising more than $21.1 million from early supporters. The Bonus Round is now live at a fixed token price of $0.007125, marking the final opportunity for contributors to access Lightchain AI tokens before the mainnet launch scheduled for July 2025.

SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Zentalis^® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on July 1, 2025, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 14,000 shares of the Company’s common stock to one (1) newly hired employee. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to such individual’s entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).